Capital Advisory Group Advisory Services LLC Invests $292,000 in Pfizer Inc. (NYSE:PFE)

Capital Advisory Group Advisory Services LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,998 shares of the biopharmaceutical company's stock, valued at approximately $292,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wells Trecaso Financial Group LLC raised its position in Pfizer by 2.5% in the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock worth $416,000 after purchasing an additional 350 shares during the period. Washington Trust Advisors Inc. boosted its position in Pfizer by 0.7% during the third quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company's stock valued at $1,424,000 after buying an additional 360 shares during the period. PSI Advisors LLC grew its stake in shares of Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after buying an additional 385 shares during the last quarter. Western Pacific Wealth Management LP increased its holdings in shares of Pfizer by 10.5% in the third quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company's stock worth $118,000 after buying an additional 386 shares during the period. Finally, Waddell & Associates LLC lifted its stake in shares of Pfizer by 1.6% in the 3rd quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company's stock valued at $723,000 after acquiring an additional 388 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on PFE. Guggenheim restated a "buy" rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Bank of America reissued a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Finally, Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $31.92.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Up 1.6 %

Shares of PFE stock traded up $0.42 during midday trading on Friday, reaching $26.32. 54,560,140 shares of the stock were exchanged, compared to its average volume of 38,524,395. The firm has a market cap of $149.14 billion, a PE ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company's 50 day moving average is $26.28 and its two-hundred day moving average is $27.44. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a boost from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. The ex-dividend date is Friday, January 24th. Pfizer's dividend payout ratio (DPR) is 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.